<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="317">
  <stage>Registered</stage>
  <submitdate>29/08/2005</submitdate>
  <approvaldate>5/09/2005</approvaldate>
  <actrnumber>ACTRN12605000302651</actrnumber>
  <trial_identification>
    <studytitle>Effect of supplementation with Folinic Acid and Methionine on hypomethylation in children with Down syndrome</studytitle>
    <scientifictitle>An open-label study to evaluate the effect of folinic acid and methionine in order to improve the metabolic profile of children with Down syndrome</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Down Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Human genetics and inherited disorders</conditioncode1>
      <conditioncode2>Down's syndrome</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>10 children with Down syndrome and 8 healthy controls will be supplemented for four months with folinic acid (400micrograms) and methionine (400mg) per day (supplied in one capsule by Thorne Research Inc, PO Box 25, Idaho, USA 83825) Blood tests for metabolic markers on methylation and immune status will be taken on day 0 (the day before supplementation starts), day 120 (the day after supplementation finishes) and day 150 (washout).</interventions>
    <comparator>Controls: Healthy children of the same age, receiving the same treatment as the intervention group</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Normalisation of metabolic markers linked to hypomethylation</outcome>
      <timepoint>Assessed after 120 days of supplementation and again 30 days later to establish the degree of wash-out</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Improved immunity, learning ability and general health.</outcome>
      <timepoint>This is measured throughout the trial on a daily basis by the parents (on supplied diary sheets) and on a weekly basis by the researcher (phonecalls to the parents).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Children with Trisomy 21</inclusivecriteria>
    <inclusiveminage>5</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>10</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Major health problems for which they receive medication.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/08/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>SDS Pathology</primarysponsorname>
    <primarysponsoraddress>10 Lyon Park Rd
North Ryde
NSW 2113</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Rainbow Pharmaceuticals</fundingname>
      <fundingaddress>Rainbow Pahrmaceuticals
1/13 Elizabeth St
Doncaster East
VIC 3109</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Thorne Research</fundingname>
      <fundingaddress>25820 Highway 2 West
PO Box 25
Dover
Idaho 83825</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>SC&amp;CM</fundingname>
      <fundingaddress>Southern Cross University
PO Box 157
Lismore
NSW 2480</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>SDS Pathology</fundingname>
      <fundingaddress>10 Lyon Park Rd
North Ryde
NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Thorne Research</sponsorname>
      <sponsoraddress>25820 Highway 2 West
PO Box 25
Dover
Idaho 83825</sponsoraddress>
      <sponsorcountry>United States of America</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Cross University</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sarah Harvey</name>
      <address>19 Daly Ave
Wahroonga NSW 2076</address>
      <phone>+61 2 94401631 OR +61 2 94872587</phone>
      <fax />
      <email>harve@impaq.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Tini Gruner</name>
      <address>SN&amp;CM
Southern Cross University
PO Box 157
Lismore NSW 2480</address>
      <phone>+61 2 66203349</phone>
      <fax />
      <email>tgruner@scu.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>